key: cord-0759256-awavyu25 authors: Grinshpun, Albert; Rottenberg, Yakir; Ben-Dov, Iddo Z.; Djian, Esther; Wolf, Dana G.; Kadouri, Luna title: Serologic Response to COVID-19 Infection and/or Vaccine in Cancer Patients on Active Treatment date: 2021-09-27 journal: ESMO Open DOI: 10.1016/j.esmoop.2021.100283 sha: 7c13821249d6b06a2ef36e37e3c27181bf4ff67c doc_id: 759256 cord_uid: awavyu25 BACKGROUND: It was shown that immunocompromised patients have significantly reduced immunologic responses to COVID-19 vaccines. The immunogenicity of COVID-19 vaccine/infection in patients with solid tumors is reduced. We evaluated the immunologic response to COVID-19 and/or the BNT162b2 mRNA COVID-19 vaccine among cancer patients on active treatments and reviewed previous literature to identify subgroups that may require third vaccination. PATIENTS AND METHODS: Anti-SARS-CoV-2 S1/S2 antibodies were measured in a cohort of 202 cancer patients on active treatment with chemotherapy (96), immunologic (52), biologic (46), and hormonal (12) treatments for early (n=66, 32.7%) or metastatic disease (n=136, 67.3%). Of those, 172 had received two vaccine doses, and 30 had COVID-19 infection (20/30 also received one dose of vaccine). Specific anti–S receptor-binding domain (RBD) antibodies were further measured in patients with equivocal anti S1/S2 results. RESULTS: Among cancer patients, the SARS-CoV-2 antibody response rate was 89.1% (180/202) after COVID-19 vaccination or infection and 87.2% (150/172) in patients after vaccination without a history of COVID-19, compared with 100% positive serologic tests in a control group of 30 healthcare workers (p<0.001). Chemotherapy treatment was independently associated with significantly reduced humoral response to infection or vaccination, with an 81.3% response rate, compared with 96.2% in patients on other treatments (p=0.001). In vaccinated patients on chemotherapy, the positive response rate was 77.5%. In a multiple regression model, a neutralizing antibody titer (>60 AU/ml) was more likely with immunotherapy (odds ratio 2.44) and less likely with chemotherapy (odds ratio 0.39). CONCLUSIONS: Overall, both COVID-19 vaccine and natural infection are highly immunogenic among cancer patients. However, our study identifies those under chemotherapy as significantly less responsive, and with lower antibody levels. These findings justify close virological and serological surveillance along with consideration of these patients for booster (3rd dose) vaccine prioritization, as new highly spreading SARS-CoV-2 variants emerge. It was shown that immunocompromised patients have significantly reduced immunologic responses to COVID-19 vaccines. The immunogenicity of vaccine/infection in patients with solid tumors is reduced. We evaluated the immunologic response to COVID-19 and/or the BNT162b2 mRNA COVID-19 vaccine among cancer patients on active treatments and reviewed previous literature to identify subgroups that may require third vaccination. Anti-SARS-CoV-2 S1/S2 antibodies were measured in a cohort of 202 cancer patients on active treatment with chemotherapy (96), immunologic (52), biologic (46), and hormonal (12) treatments for early (n=66, 32.7%) or metastatic disease (n=136, 67.3%). Of those, 172 had received two vaccine doses, and 30 had infection (20/30 also received one dose of vaccine). Specific anti-S receptor-binding domain (RBD) antibodies were further measured in patients with equivocal anti S1/S2 results. Among cancer patients, the SARS-CoV-2 antibody response rate was 89.1% (180/202) after COVID-19 vaccination or infection and 87.2% (150/172) in patients after vaccination without a history of COVID-19, compared with 100% positive serologic tests in a control group of 30 healthcare workers (p<0.001). Chemotherapy treatment was independently associated with significantly reduced humoral response to infection or vaccination, with an 81.3% response rate, compared with 96.2% in patients on other treatments (p=0.001). In vaccinated patients on chemotherapy, the positive response rate was 77.5%. In a multiple regression model, a neutralizing antibody titer (>60 AU/ml) was more likely with immunotherapy (odds ratio 2.44) and less likely with chemotherapy (odds ratio 0.39). Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared by the World Health Organization as a global pandemic in March 2020. Cancer patients under active therapy might be at significant risk for worse outcomes. [1] [2] [3] [4] [5] [6] Following massive worldwide efforts, the Federal Drug & Food Agency (FDA) authorized emergency use of several SARS-CoV-2 vaccines, including the BNT162b2 mRNA vaccine by Pfizer. In the randomized phase III trial, the BNT162b2 vaccine was administered in two doses, 21-days apart, and was 95% effective in preventing COVID-19 (95% CI, 90.3-97.6), with an excellent safety profile. A recent study of nationwide mass vaccination in Israel confirmed similar efficacy as in the randomized trials. 8 Notably, slightly lower efficacy was reported among patients with comorbidities. 8 The immune response to infection or vaccination includes an immediate humoral response to the viral proteins, as assessed by serologic tests for antibodies to the spike and the nucleocapsid proteins among infected individuals. Memory B cells and T cells are essential for long-term immunity, with robust boosting after a single vaccine inoculation in COVID-19 recovered individuals. 9 The reported seropositivity is 98-100% in vaccinated healthy control groups in varios studies. [10] [11] [12] Yet, several studies found a reduced serologic response among immunocompromised patients. 10- evaluation of the effect of chemotherapy, immunotherapy, and biologic treatments in patients with solid tumors. This study evaluated the serologic response to COVID-19 infection and/or BNT162b2 mRNA vaccine among patients with solid tumors on various active treatments to identify subgroups that show altered seropositivity due to disease stage or specific treatments. In addition, we also compare our findings with previous studies. To assess the immunologic response of cancer patients to COVID- 19 A blood sample was collected from patients at a median of 77 days after the 2 nd vaccine (range 21-97) and 121 days after infection (range 44-271). Sera were analyzed at our virology laboratory for antibodies against the spike protein (S) (Liaison SARS-CoV-2 S1/S2 IgG, DiaSorin, Italy) with a range from 3.8 (AU/ml) to >400 AU/ml. The upper antibody titer limit was capped at >400 AU/ml; thus, the titer differences may be higher than those recorded. Results of <12 are considered negative, 12-19 equivocal, and >19 AU/ml are defined as positive serology. In addition, we considered a cutoff titer above 60 IU/ml as potentially neutralizing, as this was found to be the median antibody level in a group of patients with positive virus neutralizing assay test results. 18 Specific anti-S receptor-binding domain (RBD) antibodies (SARS-CoV-2 IgG II Quant, Abbott, USA) were further measured in 7 patients with equivocal anti S1/S2 results. Patients' results are compared to 30 serological tests performed in a control group of healthcare workers at our institution, 19 matched with regards to the post-vaccination J o u r n a l P r e -p r o o f sample timing (median 77.5 days, range 6-118 days, after the second vaccine inoculation). All patients and controls signed an informed consent approved by the institutional ethics committee. For analysis of the study populations' characteristics, continuous variables were compared using the Student's t-test, and categorical variables were compared with the chi-squared test. The data were analyzed using Software Package for Statistics and Simulation (IBM SPSS version 27, Armonk, NY) and R (also used for generating figures). The dispersion of anti S1/S2 antibody titers by patient group was plotted as linked dot-, box-and violin-plots using the 'ggplot2' package and selected paiwise ttest results were added using the 'ggsignif' package. A logistic general linear model was fitted with titer at or above 60 IU/ml as the response variable and chemotherapy, immunotherapy and biological therapy as independent variables, with resulting adjusted odds ratios (OR) reported along with 95% confidence intervals (Cis). Correlations were reported using Spearman's test with the corresponding p-p-value. A total of 238 patients underwent serologic anti-SARS-CoV-S1/S2 testing. Of them, 36 were excluded from analyses due to serologic testing after one vaccine dose (n=7) or testing within 21 days from the second vaccination (n=6). For To better elucidate the relationship with specific treatment combinations ( Table 4) Two patients in our cohort had COVID-19 after the first vaccine, a third patient was recently diagnosed, with the rapid increase in delta variant COVID-19 cases in Israel. She had metastatic breast cancer, was treated with immunotherapy and chemotherapy at the time of vaccination and had a level of 62 AU/ml 3 months before she had symptomatic COVID-19, that required intensive care. Our findings confirm an overall excellent immunogenicity as manifested by antibody response to BTN162b2 mRNA COVID-19 vaccination or COVID-19 infection, with approximately 90% serocenversion in actively treated patients with solid tumors. Although this rate is significantly lower than the 99-100% found in our control group of healthcare workers 18 and reported control groups in the literature, 10-12 it is markedly higher than the frequency in other immunocompromised patients such as chronic lymphocytic lymphoma patients 10 (39%) and liver 11 (52.5%) and kidney (44%) transplanted patients. 19 Chemotherapy treatment was independently associated with a significantly reduced rate of humoral response to infection or vaccination with 77.5% seropositivty among Interestingly, immunotherapy had an an opposite effect, with an independent (namely, chemo-and biological therapy-adjusted) OR of 2.44 for >60 AU/ml antibody evels, whereas chemotherapy had an OR of 0.39, raising the possibility that immunotherapy boosts an antibody response, when present, to potentially higher protective levels, a possibility that has been previously suggested in established vaccination programs. [21] [22] but significantly lower antibody titers in 5 patients on CDK4/6 inhibitors. 12 We also had 5 patients on CDK4/6 inhibitors that on the contrary had high antibody levels, reinforcing the need for larger patient numbers for these analyses. The specific subgroups in these studies are in part small, and the differences were not necessarily significant. However, taken together with our results, there was overall high seropositivity in patients with solid tumors on hormonal and biologic treatments or surveillance, and lower seropositivity of approximately 80% among patients on chemotherapy. A potential limitation of the current study is a lack of neutralization titer measurements among study participants. Yet, IgG antibody levels have been shown to serve as a good correlative to neutralization. 24 As for immunotherapy using checkpoint inhibitors, the possible hightened immunogenicity of the COVID-19 vaccine, as reflected by the higher OR for antibody levels of >60 AU/ml in those receiving immunotherapy, has been previously suggested in established influenza vaccination programs [21] [22] , and should be further studied in larger series of cancer patients on immunotherapy. Our study suggests a high overall antibody response rate, of more than 90%, to the COVID-19 mRNA BNT162b2 vaccine or infection among cancer patients receiving active treatment. We also extend previous studies showing that chemotherapy treatment is associated with a reduced serologic response rate of approximately 80% in solid tumor patients regardless of disease status or combination. In contrast, patients on other treatments have a response rate similar to the general population. J o u r n a l P r e -p r o o f Supp. Figure 1 . Anti-SARS-CoV-2 S1/S2 levels distribution among the study population of cancer patients, treated with various therapies. COVID-19 Severity and Outcomes in Patients with Cancer: A Matched Cohort Study Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China Patients with cancer appear more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine BNT162b2 mRNA COVID19 vaccine in a nationwide mass vaccination setting Distinct antibody and memory B cell responses in SARS-CoV-19 naïve and recovered individuals following mRNA vaccination Efficacy of the BNT162b2 mRNA vaccine in patients with chronic lymphcytic leukemia Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RAN vaccination in patients with multiple myeloma Seroconversion rates following COVID-19 vaccination among patients with cancer Immunogenicity of SARS-CoV-2 messenger RNA vaccine in patients with cancer Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated with solid tumors Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer Serologic response to COVID-19 vaccination in patients with cancer older than 80 years. J of Geriat Oncol. epub ahead of print Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively The 5-months impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients Low immunogenicity to SARS-CoV-2 vaccination among liver transplan recipient Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors. Clin Inf Dis Anti-PD1 immunotherapy for metastatic renal cancer boosted humoral immunity in a hemodialysis patient COVID-19 breakthrough infections in vaccinated health care workers BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, singlecentre, longitudinal cohort study in health-care workers